COMMUNIQUÉS West-GlobeNewswire

Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California
21/03/2024
JUPITER, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the [...]
Capricor Therapeutics to Present at Upcoming Investor Conferences
21/03/2024
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases [...]
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
21/03/2024
New Program Targets Estimated $2.5 Billion Eye Pain Market FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the [...]
Smart for Life Appoints Nutraceutical Industry Veteran Heather Granato to the Company’s Advisory Board
21/03/2024
Founder of Women In Nutraceuticals (WIN), Former VP of Numerous Industry Media Brands, and 30-Year Veteran of the Nutraceutical Industry Joins Highly Diversified Team of Advisors MIAMI, March 21, 2024 (GLOBE NEWSWIRE [...]
AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars
21/03/2024
FREMONT, CA, March 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, [...]
USDA-APHIS Determines that Yield10 Bioscience’s Omega-3 Camelina Varieties May Be Planted and Bred in the United States
21/03/2024
-Yield10 achieves significant milestone enabling ramp-up to commercial scale production of omega-3 fatty acids in Camelina -Omega-3 Camelina potentially represents a novel solution to the market need for omega-3 oils [...]
Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results
21/03/2024
Top-line Results from the NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into mid-2025 NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Landos [...]
CMR Surgical announces over 20,000 surgical cases completed using Versius
21/03/2024
Over 20,000 surgical cases completed using Versius The versatile surgical robot Versius has now been used to perform over 20,000 surgical cases across seven specialties with data collected in the clinical registry and [...]
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
21/03/2024
Achieves critical first step toward priority review voucher BASKING RIDGE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical [...]
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
21/03/2024
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time [...]
BioStem Technologies to Report Fourth Quarter 2023 Financial Results on Monday, April 01, 2024
21/03/2024
Conference Call on Monday, April 1st, at 4:30 pm ET POMPANO BEACH, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, [...]
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
21/03/2024
SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su [...]
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
21/03/2024
Top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), expected March / April 2024 On track to deliver multiple read-outs in 2024, including updated results [...]
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
21/03/2024
- Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 CHARLOTTESVILLE, Va., March 21, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage [...]
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting
21/03/2024
Four Phase 2 investigator-initiated studies of TNX-1900 (intranasal potentiated oxytocin) are ongoing for pediatric obesity, binge eating disorder, bone health in autism and social anxiety disorder TNX-2900 (intranasal [...]
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
21/03/2024
Lead program in urea cycle disorders highlights power of CAMP4’s RAP Platform™ to increase gene expression using programmable, targeted medicines, with clinical candidate moving from screen-to-clinic within 3 years [...]
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
21/03/2024
CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash equivalents will continue to fund operations into late 2024 [...]
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
21/03/2024
PYX-201 Phase 1 Part 1 trial progressing with initial data expected in the fall of 2024 PYX-106 Phase 1 trial progressing with initial data expected 2H 2024 Completed $50 million private placement Expected cash runway [...]
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
21/03/2024
Medical Review Committee approved initiation of recruitment of next cohort of patients, in alignment with dose optimization protocol First patient out of six already enrolled and treated with initial dose of 2.50 mg/kg/ [...]

Pages